Literature DB >> 6424231

Adjuvants influence the immunoglobin subclass distribution of immune responses in vivo.

L Hadjipetrou-Kourounakis, E Möller.   

Abstract

Mice were immunized against fluorescein isothiocyanate (FITC)-labelled human gamma globulin (HGG) in the absence or presence of different adjuvants. The immune response was assayed every other day with regard to both total Ig-secreting cells and FITC-specific plaque-forming cells (PFC). The adjuvants influenced the type of immune response induced to the same antigenic determinant. Thus, addition of Freund's complete (FCA) or incomplete (FIA) adjuvant preferentially led to the secretion of IgG1 PFC of an average high affinity. Most newly appearing IgG-secreting cells were also detected as FITC-specific PFC. The use of lipopolysaccharide (LPS) as an adjuvant resulted in the induction of both IgM and IgG, particularly of the IgG3 and IgG2b subclasses. However, these antibodies had relatively low affinity, and a large number of total IgG-secreting cells induced by LPS had no detectable FITC specificity. The FCA/FIA- and LPS-induced responses to FITC-HGG were additive when injected together, indicating that they act on distinct subpopulations of B lymphoid cells. The adjuvant response to LPS, but not the response to FCA/FIA, was totally absent in mice of the C3H/Hej strain, which are non-responders to the polyclonal activating properties of LPS. Finally, the response induced by FCA or FIA was T-cell-dependent and the LPS response T-cell-independent as assayed in nude mice.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6424231     DOI: 10.1111/j.1365-3083.1984.tb00923.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  9 in total

Review 1.  Old and new adjuvants.

Authors:  Amy S McKee; Philippa Marrack
Journal:  Curr Opin Immunol       Date:  2017-07-19       Impact factor: 7.486

2.  The influence of Igh-1 genes on the class and subclass distribution of oxazolone-specific antibodies.

Authors:  G László; E Rajnavölgyi; I Andó; J Gergely
Journal:  Immunogenetics       Date:  1985       Impact factor: 2.846

3.  Outer membrane proteins as a carrier for detoxified lipooligosaccharide conjugate vaccines for nontypeable Haemophilus influenzae.

Authors:  T H Wu; X X Gu
Journal:  Infect Immun       Date:  1999-10       Impact factor: 3.441

4.  Effect of premedications in a murine model of asparaginase hypersensitivity.

Authors:  Christian A Fernandez; Colton Smith; Seth E Karol; Laura B Ramsey; Chengcheng Liu; Ching-Hon Pui; Sima Jeha; William E Evans; Fred D Finkelman; Mary V Relling
Journal:  J Pharmacol Exp Ther       Date:  2015-01-08       Impact factor: 4.030

5.  Influence of epitope polarity and adjuvants on the immunogenicity and efficacy of a synthetic peptide vaccine against Semliki Forest virus.

Authors:  I M Fernández; A Snijders; B J Benaissa-Trouw; M Harmsen; H Snippe; C A Kraaijeveld
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

6.  Mechanism of protective immunity induced by porin-lipopolysaccharide against murine salmonellosis.

Authors:  S Muthukkumar; V R Muthukkaruppan
Journal:  Infect Immun       Date:  1993-07       Impact factor: 3.441

7.  Meningococcal lipopolysaccharide (LPS)-derived oligosaccharide-protein conjugates evoke outer membrane protein- but not LPS-specific bactericidal antibodies in mice: influence of adjuvants.

Authors:  A F Verheul; J A Van Gaans; E J Wiertz; H Snippe; J Verhoef; J T Poolman
Journal:  Infect Immun       Date:  1993-01       Impact factor: 3.441

8.  The induction of immune complex deposits in mice by peroral and parenteral administration of mercuric chloride: strain dependent susceptibility.

Authors:  P Hultman; S Eneström
Journal:  Clin Exp Immunol       Date:  1987-02       Impact factor: 4.330

9.  Interleukin-1beta partially alleviates cyclosporin A-induced suppression of IgG1 isotype response to thyroglobulin in BALB/c mice in vivo.

Authors:  S K Dalai; B Miriyala; S K Kar
Journal:  Immunology       Date:  1998-09       Impact factor: 7.397

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.